IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Legend Biotech names Novartis executive Ingrid Zhang CEO — 2dLegend Biotech appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, with interim CEO Alan Bash becoming President of CARVYKTI. Zhang, a former Novartis executive and China head, brings broad global leadership experience from AstraZeneca, Pfizer, and McKinsey as the board positions Legend for its next growth phase.

Tom Gallagher Hiring someone with McKinsey and AstraZeneca experience signals the board wants tighter global operations going forward.

Novartis’s Latest Trial Setback Sinks Stock — Sep 8, 2026

Novartis shares sink after cholesterol drug fails phase 3 test — Sep 8, 2026

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — Sep 5, 2026Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

IJRGas Industry Says Heating Costs Will Fall 14% This Winter As Another Forecast Warns Of An IncreaseSimon August · 6 min · 12h

Novartis MS pill beats Aubagio in two large phase 3 trials — Sep 1, 2026Novartis reported positive Phase 3 REMODEL-1 and REMODEL-2 results for the BTK inhibitor remibrutinib in relapsing multiple sclerosis, showing lower annualized relapse rate and meaningful reductions in disability progression versus teriflunomide and prompting worldwide regulatory filings. With remibrutinib already approved for chronic spontaneous urticaria as Rhapsido, the drug’s MS potential could become a major growth driver given its favorable safety profile and strong early sales signals.

Rachel Meyers Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.

YourlistRankingMost Influential Women in World HistoryFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.1379 votes · 26 candidates

Novartis Plans 140 Billion Won RLT Hub in KoreaBusiness — Jul 21, 2026Novartis will invest about 140 billion won to build Korea’s domestic radioligand therapy ecosystem, including local manufacturing, advanced cold-chain logistics, and a plan to train RLT specialists while expanding treatment sites from 10 to 30 hospitals. In partnership with the Ministry of Health and Welfare, the move aims to boost Korea’s RLT research, development, and manufacturing capabilities and improve access for cancer patients.

European stocks rise as oil lifts energy sharesFinance — Jul 21, 2026European shares edged higher as tech and AI-linked gains supported markets, with indices like the STOXX 600 and Euro STOXX 50 advancing while oil prices eased on U.S.-Iran mediation hopes amid the Yemen blockade. Gains were led by chipmakers such as ASML, ASMI and Infineon, with banks and Novartis also boosting sentiment ahead of upcoming earnings reports.

XY Capital Expands Holdings Across Global Stocks — Jul 22, 2026XY Capital Ltd disclosed new or increased positions across five companies in Q1: Novartis, Yum China, Infosys, MINISO Group Holding, and NIO, with specific share purchases ranging from roughly 8,770 to 444,350 shares and portfolio weights from about 2.7% to 8.8%. Yum China became XY Capital’s largest holding, while MINISO and NIO occupy mid-range positions as the firm expands its diversified equity exposure.